Overview

Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN

Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine whether or not cyclosporine (CsA) combined with RTX is more effective than RTX alone in the treatment of idiopathic membranous nephropathy (iMN).
Phase:
Phase 3
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Beijing Tongren Hospital
Chinese Academy of Medical Sciences, Fuwai Hospital
First Affiliated Hospital of Xinjiang Medical University
Nanyang Nanshi Hospital of Henan University
Shanghai Fosun Pharmaceutical Development Co, Ltd.
The Luhe Teaching Hospital of the Capital Medical University
The Seventh Affiliated Hospital of Sun Yat-sen University
The Seventh Affiliated Hospital, Sun Yat-sen University
Treatments:
Cyclosporine
Cyclosporins
Rituximab